$VIR

Eli Lilly's Foundayo received a positive CHMP opinion for EU marketing authorization for weight management and type 2 diabetes. Roche's Enspryng gained FDA approval for thyroid eye disease. AstraZeneca partnered with insitro for AI-driven drug discovery in MASH and cardiomyopathies. The FDA launched a Rare Disease Framework Initiative to improve drug development for rare diseases. Gilead and Vir Biotechnology agreed to a $1.87 billion collaboration for masked T-cell engagers.

Roche (RHHBY) and Teva (TEVA) gained FDA approvals for new treatments. Mesa Labs (MLAB) and GSK (GSK) announced job cuts. Labcorp (LH) and AstraZeneca (AZN) made strategic deals. Vir (VIR) partnered with Gilead (GILD) for cancer immunotherapy. Galderma (GALD.SW) to acquire ZO Skin Health for $1.5B. Zealand Pharma (ZEAL.CO) partnered with Generate Biomedicines for AI drug discovery.

Vir Biotechnology (VIR) shares rose nearly 10% premarket on October 14, 2026, after announcing a $1.9B licensing deal with Gilead Sciences. The agreement focuses on Vir's PRO-XTEN technology for developing T-cell engager candidates. Vir's P/S ratio is 5.65, below its historical median of 17.0x, and its GF Score is 51, indicating moderate financial health. The company received $135M upfront, with potential milestone payments and royalties.

Vir Biotechnology, Inc. (VIR) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Exhibit 99.1 Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN ® Dual-masked T-cell Engagers for Solid Tumors - Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled pro

The FDA granted fast track status to Vir Biotechnology's VIR-5500 for metastatic prostate cancer and Perspective Therapeutics' [²¹²Pb]PSV359 for rare FAP-positive tumors. VIR-5500 showed promising phase 1 results, with 82% of patients achieving a 50% PSA decline. Both companies plan to advance development with FDA collaboration. Vir is developing VIR-5500 with Astellas Pharma.

Vir Biotechnology, Inc. (VIR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Vir Biotechnology Announces PSMA-targeted PRO-XTEN ® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer SAN FRANCISCO, Calif. October 6, 2026 - Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.

H.C. Wainwright raised its price target for Vir Biotechnology (VIR) to $22 from $20, maintaining a Buy rating. The stock is up over 90% year-to-date. The firm increased its success probability for VIR-5500 in prostate cancer to 40%. Vir reported Q2 2026 net income of $80.1M, driven by an Astellas collaboration payment. Raymond James reiterated a Strong Buy rating with a $19 target.

Vir Biotechnology (VIR) has appointed David Liu as executive vice president and chief medical officer, effective October 12, 2026. Liu will oversee clinical development, medical affairs, and regulatory affairs for the company.

Vir Biotechnology (VIR) appointed Aziz Sawaf as Executive VP and CFO, effective October 5, 2026. Brent Sabatini will cease interim principal financial officer duties but continue as SVP and Chief Accounting Officer. Sawaf previously served as CFO at Theravance.

Vir Biotechnology, Inc. (VIR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer SAN FRANCISCO, Calif. October 1, 2026 – Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Aziz Sawaf, MBEE, MBA, CFA, as Executive Vice President and Chief Financial Officer (CFO), effective O